All In Biotech

Drug Trial Radar · NCT02431845

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 1, 2013

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Severance HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

  • SSRIsDrug

    usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Yale-Brown Obsessive-Compulsive ScaleTime frame: baseline, 3 or 4 months, 6 months, 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yonsei Univ. Health System Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.